Detected ·
Specific Biologics
$35MSeries A
Specific Biologics closed an oversubscribed US$35M Series A financing, led by Hatteras Venture Partners, to advance its Dualase® gene-editing platform for C9orf72-associated ALS.
- Website
- —
- linkedin.com/company/18991581
- Amount
- $35 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-03 08:09:52 UTC
- Signal ID
- f678d97c-8b99-4d3b-a2d8-5a0046a203e9
As the API returns it
{
"id": "f678d97c-8b99-4d3b-a2d8-5a0046a203e9",
"created_at": "2026-11-03T08:09:52.209288Z",
"company_name": "Specific Biologics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/18991581",
"event_type": "funding",
"funding_amount": 35000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Specific Biologics closed an oversubscribed US$35M Series A financing, led by Hatteras Venture Partners, to advance its Dualase® gene-editing platform for C9orf72-associated ALS.*"
}